A D1 Agonist For Working Memory

• Status: Completed
• Trial end date: 2018-01-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to examine the effects of the administration of a drug called DAR-0100A on attention and memory in persons with schizotypal personality disorder (SPD). DAR-0100A has not been FDA approved, however in recent studies has been used to treat cognitive deficits, meaning problems in the way you organize your thinking, in people diagnosed with schizophrenia.

Many people who carry a diagnosis of schizotypal personality disorder have trouble with attention and memory. Increasing the presence of a brain chemical called dopamine has been found to help people with schizophrenia with their attention and memory problems. This study will investigate whether the same is true for people with schizotypal personality disorder by using DAR-0100A, a drug that has been shown to help with the cognitive deficits of people with Parkinson's disease by increasing dopamine effects. Information collected in this experiment may lead to a better understanding of the brain mechanisms involved in schizotypal personality disorder and improve treatments for the psychological problems associated with this condition.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Antonia New
• Collaborators: National Institute of Mental Health (NIMH); New York State Psychiatric Institute
• Treatments: Dihydrexidine; Dopamine

Criteria

Inclusion Criteria:

• Currently meeting DSM-IV-TR criteria for Schizotypal

• Personality Disorder

• Males and Females 18 ≤ age ≤ 65

• Medically and neurologically healthy

• Willing and having capacity to provide informed consent

Exclusion Criteria:

• Currently bipolar I disorder, schizophrenia or current psychosis

• Clinically significant cardiovascular or neurological conditions, uncontrolled hypertension, clinically significant EKG abnormalities, or serious general medical illness

• Clinical evidence of dehydration or significant hypotension

• Currently meeting DSM-IV-TR criteria for Major Depressive Disorder

• Current substance abuse or past dependence within the last six months (other than nicotine)

• Currently taking psychotropic medications

• Currently pregnant or lactating

• Non-English speaking

• Socio-economically disadvantaged people will be included in our research study.